Suspended

Deep Brain Stimulation of LHA for Energy Balance in Chronic Refractory Obesity

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
Study Aim

This study aims to treat chronic refractory obesity by applying Deep Brain Stimulation to the LHA area of your brain, with the primary focus on evaluating the safety and complication rates associated with this procedure.

What is being tested

DBS of the LHA

Device
Who is being recruted

Behavior+8

+ Behavior, Animal

+ Body Weight

From 22 to 65 Years
See all eligibility criteria
How is the trial designed

Treatment Study

Interventional
Study Start: February 2022
See protocol details

Summary

Principal Sponsordonald whiting
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: February 7, 2022

Actual date on which the first participant was enrolled.

This study focuses on a treatment approach for chronic refractory obesity, a condition where individuals have a body mass index (BMI) of 50 kg/m2 or higher and have not responded to traditional therapies. The treatment involves a procedure called Deep Brain Stimulation (DBS) of the Lateral Hypothalamic Area (LHA), using a device known as the Boston Scientific Vercise Gevia DBS system. The main goal is to assess the safety of this current-driven device compared to a previous voltage-driven system used for the same purpose. The study is important because, if successful, it could offer a new, non-destructive, adaptable, and reversible neurosurgical option to help severely obese adults alter their eating habits and achieve sustained weight loss. Six participants with chronic refractory obesity will receive DBS implants in the LHA. The procedure involves two parts: the implantation of the DBS electrodes and a subsequent test to determine the optimal settings for the LHA stimulation. The study will measure the safety of the procedure by monitoring adverse events. It will also evaluate if DBS of the LHA can influence energy balance, which includes energy intake and expenditure. Additionally, the study will look at changes in feeding behaviors and quality of life outcomes for the participants.

Official TitlePilot Study to Evaluate Deep Brain Stimulation (DBS) of the Lateral Hypothalamic Area (LHA) on Energy Balance and Feeding Behavior in Patients With Chronic Refractory Obesity
NCT04453020
Principal Sponsordonald whiting
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.



Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

From 22 to 65 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

BehaviorBehavior, AnimalBody WeightFeeding BehaviorNutrition DisordersNutritional and Metabolic DiseasesObesitySigns and SymptomsPathological Conditions, Signs and SymptomsOvernutritionOverweight

Criteria

Inclusion Criteria: 1. Male and female patients age ≥ 22 years and \< 65 years old with a BMI of ≥ 40 kg/m2. 2. Failure of bariatric surgery (gastric bypass) and subjects who have no endoscopically or surgically correctable causes for failed bariatric surgery. "Failed bariatric surgery" is determined using the modified Reinhold classification as patients who are currently more than 50% over ideal body weight at least 24 months after a technically successful surgery (as confirmed by a esophagogastroduodenoscopy (EGD) within the 6 months prior to ICF). 3. Stable at their present weight (+/- 3 kg) for a 12-month period. 4. Neuropsychiatric evaluation must not reveal any issues that will be an impediment to subject's participation (as listed in Exclusion Criteria 2, 3 and 4). 5. Karnofsky Performance Score \>60. 6. Platelet count \>125,000 per cubic mm. 7. Prothrombin time (PT) and partial thromboplastin time (PTT) within normal limits. Exclusion Criteria: 1. Any intracranial abnormality or medical condition that would contraindicate DBS surgery. 2. Have a history that includes a prior suicide attempt. 3. Have any significant psychiatric condition likely to compromise the subject's ability to comply with requirements of the study protocol (e.g. bipolar, schizophrenia, mood disorder with psychotic features, cluster B personality disorders) or have any prior history of schizophrenia or bipolar disorder or active psychotic episodes. 4. Have a current diagnosis of major depressive episode per DSM-IV (Diagnostics and Statistical Manual of Mental Disorders) criteria or has a current BDI-II score ≥ 17. 5. Any current drug or alcohol abuse, per DSM-IV criteria or any history of substance abuse (alcohol or other drug) or dependence during the past 12 months. 6. Any history of recurrent or unprovoked seizures. 7. Any history of hemorrhagic stroke. 8. Any diagnosis of acute myocardial infarction or cardiac arrest within previous 6 months. 9. Any diagnosis of a neurological disorder, such as multiple sclerosis, stroke, Parkinson's disease, severe brain atrophy or the presence of subdural hygromas or subdural hematomas. 10. Any history of hypothyroidism. 11. Any history of demonstrated binge eating. 12. Concurrent use of weight-loss prescription drug therapy or the use of over-the-counter weight loss preparations. 13. Any prior intracranial surgery or device implantation. 14. Any other active implanted devices (e.g., spinal cord stimulator, cochlear implant, pacemaker, vagus nerve stimulator) and /or drug delivery pumps, whether turned on or off. Passive implants (e.g., knee prostheses) would be allowed provided that they would not interfere with the DBS. 15. Any previously implanted Vagus Nerve Stimulation (VNS) patients. 16. A condition requiring or likely to require the use of Magnetic Resonance Imaging (MRI), diathermy or electroconvulsive therapy (ECT). 17. Likely to require the use of monopolar cautery, radio-frequency (RF) procedures, external defibrillation, lithotripsy, radiation therapy or transcranial stimulation. 18. Currently on any anticoagulant medications that cannot be discontinued during perioperative period. 19. Have any significant medical condition that is likely to interfere with study procedures or likely to confound evaluation of study endpoints, (e.g. hepatitis or HIV). 20. Any terminal illness with life expectancy of \< 1 year. 21. Any diagnosis of malignancy (except basal cell of skin) within the past five years. 22. Any unresolved infection, a coagulopathy or significant cardiac or other medical risk factor for surgery. 23. Current or future risk of being immunocompromised (due to medications, disease factors, illness, etc.) that might significantly increase risk of infection. 24. Participation in any other clinical trial (e.g. drug, device, or biologics) concurrently or within the preceding 30 days. Participation in any other study will be allowed per investigator/sponsor discretion only. 25. Plan to receive any procedure that involves sudden jerking motions of the head or neck (e.g. certain chiropractic therapies) or massage and manipulation directly over the leads in the scalp, neck or chest, at any time during the study. 26. A female who is breastfeeding or of child-bearing potential with a positive urine pregnancy test or not using adequate contraception. 27. Not able to speak, write and read in English language as determined by the investigator. 28. Overall intellectual abilities below a standard score of 80 based on results from the Wechsler Abbreviated Scale of Intelligence (WASI; Wechsler, 1999) 29. Unable to fit into MRI or CT (Maximum weight limit is 180 kg (396 lb.). 30. Plasma pre-albumin \< 14 mg/dL 31. Obesity as part of another medical condition, neurological injury or lesions, related to medication side effect, or as part of a genetic syndrome (i.e. Prader-Willi Syndrome, Leptin deficiency, etc.) 32. Be eligible for bariatric surgery revision including gastric outlet exclusion, gastrogastric fistula or other reasons that would qualify for a revision of their gastric bypass 33. Unable or unwilling to follow up for scheduled clinic visits

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

One single intervention group is designated in this study

This study does not include a placebo group 

Treatment Groups

Group I

Experimental
Subjects will receive bilateral DBS of the LHA

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Suspended

Allegheny General Hospital

Pittsburgh, United StatesOpen Allegheny General Hospital in Google Maps
SuspendedOne Study Center